Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, shares her thoughts on the most exciting agents under investigation in clinical trials for the treatment of multiple sclerosis (MS). A large number of ongoing trials are assessing the safety and efficacy of BTK inhibitors, both in relapsing-remitting disease and progressive disease. It is thought that BTK inhibitors may exert a neuroprotective influence via targeting of the innate immune system, on top of their established anti-inflammatory activity. In this way, this drug class has the potential to become a very valuable option to treat progressive disease. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.